The UK uses AI to make medicines safer and reduce animal testing
英國利用人工智慧使藥物更安全並減少動物實驗
更新於: 2026年6月10日 上午08:30
The UK is transforming its approach to medical research by integrating artificial intelligence to modernize drug development.
英國正藉由整合人工智慧來徹底改造醫學研究，以實現藥物開發的現代化。
As part of a national strategy to prioritize ethical, human-relevant science, the UK is actively working to replace traditional animal testing with advanced technologies.
作為優先推動合乎道德且與人類相關之科學的國家策略的一部分，英國正積極致力於以先進技術取代傳統的動物實驗。
By replacing animal trials with AI-driven analysis, organ-on-a-chip systems, and 3D bioprinted tissues, the government aims to reduce the high economic and personal costs of adverse drug reactions.
透過以人工智慧驅動的分析、晶片器官系統以及3D生物列印組織來取代動物試驗，政府旨在降低藥物不良反應所帶來的沉重經濟與個人成本。
Supported by a £75 million investment, the UK has set ambitious milestones, including banning certain animal tests for skin and eye irritation by 2026 and targeting a reduction in dog and primate studies by 2030.
在7500萬英鎊的資金支持下，英國制定了雄心勃勃的里程碑，包括在2026年前禁止某些針對皮膚與眼睛刺激的動物測試，並計畫在2030年前減少犬類與靈長類動物的研究。
This shift is not just about animal welfare; it is a strategic move to accelerate the delivery of safe, innovative treatments while positioning the UK as a global leader in modern, data-driven healthcare.
此轉變不僅是為了動物福祉，更是為了加速提供安全、創新的治療方法，同時將英國定位為現代數據驅動型醫療保健的全球領導者。
